Appendix 1

Author Relationships With Industry and Other Entities—ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

Committee MemberConsulting Fees/HonorariaSpeaker's BureauOwnership/Partnership/PrincipalResearch GrantBoard of DirectorsExpert Witness or Consultant
Dr. Vallerie V. McLaughlin (Chair)
  • Actelion*

  • CoTherix*

  • Gilead/Myogen*

  • Pfizer

  • Actelion*

  • CoTherix

  • Gilead/Myogen

  • Pfizer

None
  • Actelion*

  • CoTherix*

  • Encysive*

  • Lung Rx*

  • Pfizer*

  • United Therapeutics*

NoneNo
Dr. Stephen L. ArcherNoneNoneNoneNoneNoneNo
Dr. David Badesch
  • Actelion*

  • Amgen

  • CoTherix*

  • Encysive*

  • Gilead/Myogen*

  • GlaxoSmithKline

  • InterMune

  • Mondo Biotech

  • Pfizer*

  • PR Pharmaceuticals

  • Scios

  • United Therapeutics/Lung Rx

NoneNone
  • Actelion*

  • CoTherix*

  • Encysive*

  • Gilead/Myogen*

  • Lilly/ICOS*

  • Pfizer*

  • United Therapeutics/Lung Rx

• Pulmonary Hypertension AssociationYes. Diet drug litigation.
Dr. Robyn J. Barst
  • Actelion*

  • CoTherix*

  • Encysive*

  • Generamedix

  • Gilead/Myogen

  • GlaxoSmithKline

  • INO Therapeutics*

  • Lung Rx

  • Medtronic

  • MondoBIOTECH

  • Pfizer*

  • Novartis

  • United Therapeutics*

  • Actelion*

  • CoTherix*

  • Encysive*

  • Gilead

  • INO Therapeutics

  • Pfizer*

None
  • Actelion*

  • CoTherix*

  • Encysive*

  • Gilead/Myogen

  • INO Therapeutics*

  • Lung Rx

  • Medtronic

  • MondoBIOTECH

  • Novartis

  • Pfizer*

  • United Therapeutics*

NoneYes. Diet drug litigation.
Dr. Harrison W. Farber
  • Actelion

  • Gilead/Myogen

  • United Therapeutics

  • Actelion

  • Encysive

  • Gilead/Myogen

  • Pfizer

None
  • Actelion

  • Epix

  • Gilead

  • Scios*

NoneNo
Dr. Jonathan R. LindnerNoneNoneNoneNoneNoneNo
Dr. Michael A. Mathier
  • Actelion*

  • Gilead/Myogen

  • Actelion*

  • CoTherix

  • Encysive

  • GlaxoSmithKline

  • Scios

None• Actelion*NoneNo
Dr. Michael D. McGoon
  • Actelion

  • CoTherix*

  • Medtronic

  • United Therapeurtics

NoneNone
  • Actelion*

  • CoTherix*

  • Encysive

  • Gilead/Myogen*

  • Medtronic*

  • Pfizer*

  • United Therapeutics

NoneNo
Dr. Myung H. Park
  • Actelion*

  • CoTherix

  • Encysive

  • Pfizer

  • United Therapeutics

  • Actelion*

  • CoTherix

  • Encysive

  • Pfizer

  • United Therapeutics

None
  • Actelion*

  • CoTherix

NoneNo
Dr. Robert S. Rosenson
  • Abbott

  • Anthera

  • AstraZeneca*

  • Daiichi Sankyo

  • LipoScience

  • Roche

None• LipoScience*None• Grain BoardNo
Dr. Lewis J. Rubin
  • Actelion*

  • Aires

  • CoTherix*

  • Encysive*

  • Gilead/Myogen*

  • Mondo Biotech

  • Pfizer

  • United Therapeutics*

None
  • Aires

  • United Therapeutics*

  • Actelion*

  • CoTherix*

  • Gilead/Myogen*

  • Pfizer*

  • United Therapeutics*

NoneYes. Diet drug litigation (plaintiff).
Dr. Victor F. Tapson
  • Actelion*

  • CoTherix*

  • Encysive

  • Gilead/Myogen*

  • Lungs Rx*

  • Pfizer

  • United Therapeutics

  • Actelion*

  • Gilead/Myogen*

None
  • Actelion*

  • CoTherix*

  • Encysive*

  • Gilead/Myogen*

  • Lungs Rx*

  • Pfizer*

  • United Therapeutics*

NoneYes. Diet drug litigation.
Dr. John Varga• Actelion*NoneNoneNoneNoneNo

This table represents the relevant relationships of committee members with industry and other entities that were reported orally at the initial writing committee meeting and updated in conjunction with all meetings and conference calls of the writing committee during the document development process. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10 000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships noted in this table are modest unless otherwise noted.

  • * Significant (greater than $10 000) relationship.